

30 May 2023

ASX Market Announcements Office  
ASX Limited  
Level 4, North Tower, Rialto  
525 Collins Street  
Melbourne VIC 3000

By electronic lodgement

Dear Ms Kostopoulos,

## Micro-X Limited (MX1) – Price Query

Micro-X Limited (ASX:MX1) (ACN 153 273 735) (**MX1**) responds to ASX request for information (reference 75005) as follows

1. No.
2. N/A.
3. MX1 released an ASX announcement yesterday (29 May 2023) in respect of its successful field testing on Argus (**Argus Announcement**), which may explain the increase in share price and increase in the volume of securities traded today. Other than the details set out in the Argus Announcement, MX1 has no other explanation for the recent trading in its securities.
4. MX1 is complying with the Listing Rules, including Listing Rule 3.1.
5. MX1's responses to ASX's questions have been authorised and approved by the Chair of MX1's Audit and Risk Committee.

Yours sincerely



Kingsley Hall  
Chief Executive Officer  
Micro-X Limited

– ENDS –

## About Micro-X

Micro-X Limited (the **Company**) is an ASX listed hi-tech company developing and commercialising a range of innovative products for global health and security markets, based on proprietary cold cathode, carbon nanotube (CNT) emitter technology. The electronic control of emitters with this technology enables x-ray products with significant reduction in size, weight and power requirements, enabling greater mobility and ease of use in existing x-ray markets and a range of new and unique security and defence applications. Micro-X has a fully vertically integrated design and production facility in Adelaide, Australia. A growing technical and commercial team based in Seattle is rapidly expanding Micro-X's US business.

Micro-X's product portfolio is built in four, high margin, product lines in health and security. The first commercial mobile digital radiology products are currently sold for diagnostic imaging in global healthcare, military and veterinary applications. An X-ray Camera for security imaging of Improvised Explosive Devices is in advanced development. The US Department of Homeland Security has selected Micro-X to design a next-generation Airport Checkpoint Portal with self-service x-ray. A miniature brain CT imager for pre-hospital stroke diagnosis in ambulances, is being developed with funding from the Australian Government's Medical Research Future Fund.

For more information visit: [www.micro-x.com](http://www.micro-x.com)

## CONTACTS

Micro-X Limited	Investor Enquiries
<b>Kingsley Hall</b> , Chief Executive Officer <b>Rebecca Puddy</b> , Head of Corporate Communications Tel: +61 8 7099 3966 E: <a href="mailto:media@micro-x.com">media@micro-x.com</a>	<b>David Allen / John Granger</b> Hawkesbury Partners Tel: +61 2 9103 9494 E: <a href="mailto:dallen@hawkesburypartners.com">dallen@hawkesburypartners.com</a> <a href="mailto:jgranger@hawkesburypartners.com">jgranger@hawkesburypartners.com</a>



30 May 2023

Reference: 75005

Mr Kingsley Hall  
Company Secretary  
Micro-X Limited  
A14, 6 MAB Eastern Promenade  
Tonsley, Clovelly Park  
South Australia, 5042

By email: khall@micro-x.com

Dear Mr Hall

**Micro-X Limited ('MX1'): Price - Query**

ASX refers to the following:

- A. The change in the price of MX1's securities from a low of \$0.09 at close of trading yesterday to a high of \$0.125 today.
- B. The significant increase in the volume of MX1's securities traded today.

**Request for information**

In light of this, ASX asks MX1 to respond separately to each of the following questions and requests for information:

1. Is MX1 aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is MX1 relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in MX1's securities would suggest to ASX that such information may have ceased to be confidential and therefore MX1 may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that MX1 may have for the recent trading in its securities?
4. Please confirm that MX1 is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that MX1's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of MX1 with delegated authority from the board to respond to ASX on disclosure matters.

### When and where to send your response

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **3:00 PM AEST Tuesday, 30 May 2023**. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, MX1's obligation is to disclose the information 'immediately'. This may require the information to be disclosed before the deadline set out in the previous paragraph and may require MX1 to request a trading halt immediately.

Your response should be sent to me by e-mail at [ListingsComplianceMelbourne@asx.com.au](mailto:ListingsComplianceMelbourne@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### Trading halt

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in MX1's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted. You can find further information about trading halts in Guidance Note 16 *Trading Halts & Voluntary Suspensions*.

### Suspension

If you are unable to respond to this letter by the time specified above, ASX will likely suspend trading in MX1's securities under Listing Rule 17.3.

### Listing Rules 3.1 and 3.1A

In responding to this letter, you should have regard to MX1's obligations under Listing Rules 3.1 and 3.1A and also to Guidance Note 8 *Continuous Disclosure*: Listing Rules 3.1 – 3.1B. It should be noted that MX1's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### Release of correspondence between ASX and entity

ASX reserves the right to release all or any part of this letter, your reply and any other related correspondence between us to the market under Listing Rule 18.7A.

### Questions

If you have any questions in relation to the above, please do not hesitate to contact me.

Regards

---

**Melissa Kostopoulos**  
Adviser, Listings Compliance